ANTX

AN2 Therapeutics Announces FDA Clearance of IND Application for Epetraborole in Polycythemia Vera

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for epetraborole in polycythemia vera (PV). The Company has now received regulatory clearance in all planned jurisdictions (Australia, India, and the U.S.) for the global study and expects to initiate the trial in the fourth quarter of 2026.

“We’re pleased to receive FDA IND clearance and the necessary authorizations globally to advance epetraborole into Phase 2 clinical development for polycythemia vera,” said Cameron Trenor, M.D., Chief Medical Officer of AN2 Therapeutics. “Extensive preclinical and human data generated to date indicate that epetraborole has the potential to produce early, controlled, sustained and dose-dependent control of hematocrit, providing a strong rationale for clinical development in PV. We anticipate initiating the Phase 2 trial in the fourth quarter of 2026.”

About the Phase 2 Study of Oral Epetraborole in PV

The planned Phase 2 study consists of an open-label epetraborole sentinel cohort, an open-label dose optimization cohort for dose selection (Part 1), followed by a double-blind, randomized, placebo-controlled cohort (Part 2), and an optional open-label extension cohort (Part 3). The study is designed to assess the efficacy of oral epetraborole in phlebotomy-dependent adults with PV and its effect on key hematological variables, to optimize a dose regimen on a by-patient level, to assess safety and tolerability, and and to assess patient-reported outcomes (PROs) using validated PRO instruments.

About Polycythemia Vera (PV)

PV is a blood cancer characterized by overproduction of red blood cells in the bone marrow. This overproduction increases hematocrit which can lead to serious medical complications, including arterial and venous thromboembolic events. If untreated, PV can be life-threatening. Despite available therapies, many patients experience uncontrolled hematocrit levels and persistent symptom burden, requiring long term management to maintain adequate disease control. PV is estimated to affect approximately 155,000 people in the U.S.

About AN2 Therapeutics

AN2 Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from our boron chemistry platform. Our development pipeline spans hematologic diseases, infectious diseases, and oncology with three Phase 2 programs expected to be active in 2026, as well as preclinical and research programs focused on targets in oncology, bone disorders, and infectious diseases. We are committed to delivering high-impact drugs to patients that address critical unmet needs and improve health outcomes.

Announced: November 2, 2026